Table 2.
Additional characteristics by surgery type and cohort
| RALP | RRP (total) | RRP (PCOS) | RRP (CEASAR) | p Value*
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test 1* | Test 2† | |||||||||
| No. pts | 933 | 1,505 | 1,243 | 262 | ||||||
| Clinicopathological characteristics | ||||||||||
| No. pathological staging (%): | ||||||||||
| pT2 | 735 | (78.8) | 1,015 | (67.4) | 810 | (65.2) | 205 | (78.2) | <0.001‡ | <0.001‡ |
| pT3 (not otherwise specified) | 4 | (0.4) | 105 | (7.0) | 100 | (8.0) | 5 | (1.9) | ||
| pT3a | 114 | (12.2) | 202 | (13.4) | 179 | (14.4) | 23 | (8.8) | ||
| pT3b | 32 | (3.4) | 108 | (7.2) | 92 | (7.4) | 16 | (6.1) | ||
| pT4 | 0 | (0.0) | 42 | (2.8) | 42 | (3.4) | 0 | (0.0) | ||
| Other | 3 | (0.3) | 9 | (0.6) | 6 | (0.5) | 3 | (1.1) | ||
| Missing | 45 | (4.8) | 24 | (1.6) | 14 | (1.1) | 10 | (3.8) | ||
| Median ng/ml PSA (IQR) | 5.0 | (4.1–6.7) | 6.6 | (4.8–9.9) | 6.9 | (5.0–10.5) | 5.2 | (4.2–7.6) | <0.001§ | <0.001§ |
| No. PSA missing (%) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
| No. Gleason score (%): | <0.001‡ | <0.001‡ | ||||||||
| 6 or Less | 294 | (31.5) | 762 | (50.6) | 664 | (53.4) | 98 | (37.4) | ||
| 7 | 557 | (59.7) | 462 | (30.7) | 333 | (26.8) | 129 | (49.2) | ||
| 8–10 | 59 | (6.3) | 126 | (8.4) | 96 | (7.7) | 30 | (11.5) | ||
| Missing | 23 | (2.5) | 155 | (10.3) | 150 | (12.1) | 5 | (1.9) | ||
| No. neg margins (%): | 710 | (76.1) | 936 | (62.2) | 756 | (60.8) | 180 | (68.7) | <0.001‡ | <0.001‡ |
| Missing | 28 | (3.0) | 100 | (6.6) | 92 | (7.4) | 8 | (3.1) | ||
| No. nerve sparing (%): | 728 | (78.0) | 702 | (46.6) | 517 | (41.6) | 185 | (70.6) | <0.001‡ | <0.001‡ |
| Missing | 145 | (15.5) | 302 | (20.1) | 242 | (19.5) | 60 | (22.9) | ||
| No. comorbidities (%): | <0.001‡ | 0.001‡ | ||||||||
| 0 | 355 | (38.0) | 794 | (52.8) | 717 | (57.7) | 77 | (29.4) | ||
| 1 | 362 | (38.8) | 452 | (30.0) | 344 | (27.7) | 108 | (41.2) | ||
| 2 | 114 | (12.2) | 163 | (10.8) | 131 | (10.5) | 32 | (12.2) | ||
| 3 or Greater | 26 | (2.8) | 60 | (4.0) | 51 | (4.1) | 9 | (3.4) | ||
| Missing | 76 | (8.1) | 36 | (2.4) | 0 | (0.0) | 36 | (13.7) | ||
| Baseline pt reported outcomes | ||||||||||
| No. self-reported overall health (%): | <0.001‡ | <0.001‡ | ||||||||
| Poor | 6 | (0.6) | 21 | (1.4) | 17 | (1.4) | 4 | (1.5) | ||
| Fair | 35 | (3.8) | 108 | (7.2) | 90 | (7.2) | 18 | (6.9) | ||
| Good | 221 | (23.7) | 438 | (29.1) | 351 | (28.2) | 87 | (33.2) | ||
| Very good | 429 | (46.0) | 592 | (39.3) | 485 | (39.0) | 107 | (40.8) | ||
| Excellent | 240 | (25.7) | 342 | (22.7) | 296 | (23.8) | 46 | (17.6) | ||
| Missing | 2 | (0.2) | 4 | (0.3) | 4 | (0.3) | 0 | (0.0) | ||
| Median urinary function summary score (IQR) | 100.0 | (85.0–100.0) | 100 | (100.0–100.0) | 100.0 | (100.0–100.0) | 100.0 | (88.8–100.0) | <0.001§ | <0.001§ |
| Median sexual function summary score (IQR) | 86.7 | (58.3–100.0) | 88.9 | (66.7–100.0) | 93.3 | (73.3–100.0) | 79.2 | (51.7–93.3) | <0.001§ | <0.001§ |
*
Comparisons are among RALP, RRP (PCOS) and RRP (CEASAR).
†
Comparisons are between RALP (total) and RRP (total).
‡
Pearson chi-square test.
§
Kruskal-Wallis test.